BioXcel Therapeutics (BTAI) Free Cash Flow (2017 - 2026)

BioXcel Therapeutics' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$11.8 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 1.94% year-over-year to -$11.8 million; the TTM figure through Mar 2026 stood at -$57.4 million (up 13.54% YoY), while the FY2025 annual figure was -$57.6 million, up 20.01% from the prior year.
• Free Cash Flow was -$11.8 million for Q1 2026 at BioXcel Therapeutics, up from -$14.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$11.8 million in Q1 2026 to a low of -$52.4 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$25.4 million across 5 years, with a median of -$23.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow plunged 93.74% in 2022, then jumped 66.18% in 2024.
• A 5-year view of Free Cash Flow shows it stood at -$38.6 million in 2022, then soared by 30.48% to -$26.9 million in 2023, then soared by 44.87% to -$14.8 million in 2024, then advanced by 4.04% to -$14.2 million in 2025, then gained by 16.9% to -$11.8 million in 2026.
• The last three Free Cash Flow figures came in at -$11.8 million (Q1 2026), -$14.2 million (Q4 2025), and -$18.8 million (Q3 2025), per Business Quant data.